IHC

EGFR

Identifies epidermal growth factor receptor, a transmembrane protein overexpressed in various tumors including lung, breast, prostate, ovarian, brain, and especially squamous cell carcinomas. EGFR serves as a therapeutic target for agents such as gefitinib, erlotinib, and cetuximab. Its expression is linked to poor prognosis and shorter disease-free survival, with most colon carcinomas showing positivity in over 1% of tumor cells.

Synonyms

Epidermal Growth Factor Receptor

Full Description

Identifies epidermal growth factor receptor, a transmembrane protein overexpressed in various tumors including lung, breast, prostate, ovarian, brain, and especially squamous cell carcinomas. EGFR serves as a therapeutic target for agents such as gefitinib, erlotinib, and cetuximab. Its expression is linked to poor prognosis and shorter disease-free survival, with most colon carcinomas showing positivity in over 1% of tumor cells.

Methodology

IHC

Specimen Requirements

Tissue Block: Formalin-fixed, paraffin-embedded (FFPE) tumor block preferred. Unstained Slides: Recommended 2 charged slides per stain requested (minimum of 1 slide per stain), baked or unbaked. Fixation: Tissue must be fixed in 10% neutral buffered formalin for 6–72 hours.

Storage and Transportation

Use cold pack for transport. Make sure cold pack is not in direct contact with specimen.

Turnaround Time

Global: 48 Hrs, Tech-Only (stain only): 24 Hrs

CPT Codes

88342x1 or 88341x1